Transition Therapeutics Announces Second Quarter Fiscal 2008 Financi...( TORONTO Feb. 12 / Transition Ther...),Health

TORONTO, Feb. 12 /PRNewswire-FirstCall/ - Transition Therapeutics Inc. ("Transition" or the "Company") (TSX: TTH; NASDAQ: TTHI), a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets including Alzheimer's Disease and Diabetes, today announced its financial results for the quarter ended December 31, 2007.

Selected Highlights

-------------------

During the second quarter of fiscal 2008 and up to the date of this press release, the Company achieved the following significant milestones:

ELND005 (AZD-103) - Alzheimer's Disease:

- On January 22, 2008, the Company received a US$5,000,000 milestone

payment from Elan. The milestone payment was triggered by the

initiation of a Phase II clinical study of Alzheimer's disease drug

candidate, ELND005 (AZD-103) on December 21, 2007;

- On December 21, 2007, Elan and Transition Dose First Patient in

Phase II Clinical Study of ELND005 (AZD-103) in Alzheimer's Disease.

The study is a randomized, double-blind, placebo-controlled, dose-

ranging, safety and efficacy study in approximately 340 patients with

mild to moderate Alzheimer's disease. Approximately 65 sites in North

America are expected to participate in the program. The study will

evaluate both cognitive and functional endpoints and each patient's

participation is planned to last approximately 18 months;

- On October 26, 2007, the Company Received the Remaining US$7,500,000

Upfront Payment from Elan. The receipt of US$7,500,000 represents the

second half of the US$15 million upfront payment under the Company's

global collaboration agreement with Elan.

TT-223 (formerly known as "G1") - Diabetes:

- On November 5, 2007, the Company Announced an Update on the Clinical

Development and Partnership activitie
'/>"/>